Job Description
Job DescriptionSalary:
Reporting to the Associate Director of Translational Medicine, this individual will serve as an integral team member with exposure to multiple facets of research operations focused on pipeline advancement and evaluation. The Senior Research Associate I / II will be responsible for conducting immunogenicity assays to measure the efficacy of clinical vaccines and work closely with teammates on the organizations Translational Medicine team. Additional functions of the role include performing in vivo mouse experiments to characterize the immune response to the companys lead vaccine candidates.
Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts, with additional staff functioning in a virtual-based environment from the Greater Boston area and throughout the United States.
Major Duties/Responsibilities
- Execute immunogenicity and/or biomarker assays to evaluate correlates of response to therapeutic vaccination, such as ELISPOT/Fluorospot, ICS, and other flow cytometry-based assays
- Complete experimental documentation and data analysis following appropriate SOPs for investigations on clinical samples
- Perform PBMC isolations from whole blood and leukopak for research and clinical studies
- Review and author compliant documents as part of the organizations document life cycle management
- Assist with clinical sample management, including sample receipt and maintenance of the clinical sample chain of custody
- Perform murine handling, injections, and blood/organ collections
- Communicate findings in various forums and interact collaboratively with other team members
- Willingness to learn new analytical assays and assist with the advancement of novel T cell and antibody-based assays
- Perform job responsibilities in compliance with GCLP guidelines, where applicable
Education & Professional Experience
- BS with 3-5+ years of relevant work experience OR MS with 1-3+ years of experience
- Ability to take initiative and produce in a fast-paced environment
- Ability to prioritize tasks and consistently demonstrate strong decision-making and judgment skills
- Strong attention to detail, organizational skills, and the ability to manage multiple projects
- Outstanding communication (written and verbal) and interpersonal skills
- This position is based in our Boston office and requires on-site presence
Working Conditions
- Busy office/laboratory environment with frequent deadlines and interruptions
Travel
- Travel is not required
Physical Requirements
- Subject to periods of sitting or standing, vision is required to monitor data. Work is performed exclusively in an office/laboratory environment.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicios Amphiphile (AMP) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicios ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf vaccine approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized vaccines approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (CRC) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicios pipeline includes additional off-the-shelf therapeutic cancer vaccines candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.
About the Amphiphile Platform
Elicios proprietary AMP platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based on preclinical studies.
Elicios AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.
The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue.